<p>Corcept Therapeutics（纳斯达克：CORT - 获取免费报告）在周一发布给投资者的研究报告中，被 Zacks Research 的股票分析师从 “强烈卖出” 评级上调至 “持有” 评级，Zacks.com 报道。</p>
<ul>
<li>3 只生物制药股票逆势上涨</li>
</ul>
<p>其他几位分析师也对 CORT 发布了报告。Truist Financial 在 3 月 25 日的研究报告中将 Corcept Therapeutics 的评级上调至 “强烈买入”。Canaccord Genuity Group 在 3 月 26 日的研究报告中将 Corcept Therapeutics 的目标股价从 100.00 美元上调至 110.00 美元，并给予该股票 “买入” 评级。Wolfe Research 在 3 月 26 日的研究报告中将 Corcept Therapeutics 的评级从 “表现不佳” 上调至 “同业表现”。Piper Sandler 在周五将 Corcept Therapeutics 的目标股价从 73.00 美元上调至 88.00 美元，并给予该股票 “增持” 评级。最后，HC Wainwright 在周一将 Corcept Therapeutics 的目标股价从 60.00 美元上调至 75.00 美元，并给予该股票 “买入” 评级。一位分析师给予该股票 “强烈买入” 评级，三位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 74.67 美元。</p>
<p>获取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们关于 Corcept Therapeutics 的最新报告</strong></p>
<h2>Corcept Therapeutics 股票下跌 0.5%</h2>
<p>CORT 周一开盘价为 51.37 美元。该公司的 50 日简单移动平均线为 39.47 美元，200 日简单移动平均线为 54.18 美元。Corcept Therapeutics 的 52 周低点为 28.66 美元，52 周高点为 91.00 美元。该股票的市值为 55.1 亿美元，市盈率为 146.76，贝塔值为 0.36。</p>
<p>Corcept Therapeutics（纳斯达克：CORT - 获取免费报告）在 4 月 30 日最后发布了季度财报。这家生物技术公司报告季度每股收益（EPS）为（0.30）美元，低于共识预期的（0.11）美元，差距为（0.19）美元。该公司季度收入为 1.649 亿美元，而共识预期为 1.8583 亿美元。Corcept Therapeutics 的股本回报率为 7.40%，净利润率为 6.14%。该公司季度收入同比增长 4.9%。去年同期，该公司每股收益为 0.17 美元。整体来看，股票分析师预计 Corcept Therapeutics 在当前年度将发布 0.35 美元的每股收益。</p>
<h2>内部活动</h2>
<p>在其他 Corcept Therapeutics 的新闻中，董事 G Leonard Baker, Jr.在 3 月 17 日的交易中购买了 100,000 股该公司的股票。该股票的平均购买价格为每股 33.14 美元，总价值为 3,314,000.00 美元。完成购买后，该董事直接持有 1,146,631 股该公司的股票，价值约为 37,999,351.34 美元。此次交易使其持股增加了 9.55%。该购买在 SEC 的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Joseph K. Belanoff 在 3 月 25 日的交易中出售了 26,198 股 Corcept Therapeutics 的股票。该股票的平均售价为 50.07 美元，总交易额为 1,311,733.86 美元。出售完成后，首席执行官在公司中持有 2,918,326 股，价值约为 146,120,582.82 美元。此次交易使其持股减少了 0.89%。该出售的披露信息可在 SEC 备案中找到。在过去三个月中，内部人士共出售了 66,198 股公司股票，价值为 2,851,169 美元。公司内部人士持有 20.70% 的公司股票。</p>
<h2>机构投资者对 Corcept Therapeutics 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该股票的持有。Torren Management LLC 在第四季度购买了 Corcept Therapeutics 的新头寸，价值约为 25,000 美元。Advisory Services Network LLC 在第三季度购买了 Corcept Therapeutics 的新股份，价值约为 25,000 美元。Clearstead Advisors LLC 在第三季度将其在 Corcept Therapeutics 的持仓增加了 163.6%。Clearstead Advisors LLC 现在持有 311 股该生物技术公司的股票，价值为 26,000 美元，此前在上个季度又购买了 193 股。Atlas Capital Advisors Inc.在第四季度购买了 Corcept Therapeutics 的新股份，价值约为 31,000 美元。最后，Hantz Financial Services Inc.在第四季度将其在 Corcept Therapeutics 的持仓增加了 113.7%。Hantz Financial Services Inc.现在持有 985 股该生物技术公司的股票，价值 34,000 美元，此前在此期间又购买了 524 股。93.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Corcept Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Corcept Therapeutics 是一家临床阶段的生物制药公司，专注于发现和开发调节皮质醇作用的药物，皮质醇是一种与多种严重代谢、肿瘤和精神疾病相关的激素。该公司的科学平台专注于选择性靶向糖皮质激素受体，以抵消过量皮质醇的有害后果，这一策略旨在解决具有显著未满足医疗需求的疾病。</p>
<p>该公司的旗舰上市产品 Korlym（米非司酮）已在美国获得批准，用于治疗因库欣综合症引起的高血糖，适用于患有 2 型糖尿病或葡萄糖耐受不良且不适合手术的患者。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Corcept Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Corcept Therapeutics 吗？</h2>
<p>在考虑 Corcept Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Corcept Therapeutics 并不在名单上。</p>
<p>虽然 Corcept Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Corcept医疗

医疗业 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

<p>Zacks Research 将 Corcept Therapeutics (NASDAQ:CORT) 的评级从 “强烈卖出” 上调至 “持有”。其他分析师也提高了他们的评级，Truist Financial 给出了 “强烈买入” 的评级，而 Canaccord Genuity 将目标价格从 100 美元上调至 110 美元。该股票开盘价为 51.37 美元，市值为 55.1 亿美元。Corcept 报告的季度每股收益为（0.30 美元），未达到预期，但收入同比增长 4.9%。内部交易活动包括董事 G Leonard Baker, Jr. 的大额购买和首席执行官 Joseph K. Belanoff 的出售</p>

<p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) was upgraded by stock analysts at Zacks Research from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Corcept Therapeutics（纳斯达克：CORT - 获取免费报告）在周一发布给投资者的研究报告中，被 Zacks Research 的股票分析师从 “强烈卖出” 评级上调至 “持有” 评级，Zacks.com 报道。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物制药股票逆势上涨</li>
</ul>
</div><p>Several other analysts have also issued reports on CORT. Truist Financial raised Corcept Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 26th. Wolfe Research raised shares of Corcept Therapeutics from an &#34;underperform&#34; rating to a &#34;peer perform&#34; rating in a research note on Thursday, March 26th. Piper Sandler boosted their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday. Finally, HC Wainwright raised their price target on shares of Corcept Therapeutics from $60.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $74.67.</p>
<div class="lb-trans"><p>其他几位分析师也对 CORT 发布了报告。Truist Financial 在 3 月 25 日的研究报告中将 Corcept Therapeutics 的评级上调至 “强烈买入”。Canaccord Genuity Group 在 3 月 26 日的研究报告中将 Corcept Therapeutics 的目标股价从 100.00 美元上调至 110.00 美元，并给予该股票 “买入” 评级。Wolfe Research 在 3 月 26 日的研究报告中将 Corcept Therapeutics 的评级从 “表现不佳” 上调至 “同业表现”。Piper Sandler 在周五将 Corcept Therapeutics 的目标股价从 73.00 美元上调至 88.00 美元，并给予该股票 “增持” 评级。最后，HC Wainwright 在周一将 Corcept Therapeutics 的目标股价从 60.00 美元上调至 75.00 美元，并给予该股票 “买入” 评级。一位分析师给予该股票 “强烈买入” 评级，三位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 74.67 美元。</p>
</div><p>Get <strong>Corcept Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on Corcept Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Corcept Therapeutics 的最新报告</strong></p>
</div><h2>Corcept Therapeutics Stock Down 0.5%</h2>
<div class="lb-trans"><h2>Corcept Therapeutics 股票下跌 0.5%</h2>
</div><p>CORT opened at $51.37 on Monday. The business's fifty day simple moving average is $39.47 and its 200 day simple moving average is $54.18. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $91.00. The stock has a market cap of $5.51 billion, a PE ratio of 146.76 and a beta of 0.36.</p>
<div class="lb-trans"><p>CORT 周一开盘价为 51.37 美元。该公司的 50 日简单移动平均线为 39.47 美元，200 日简单移动平均线为 54.18 美元。Corcept Therapeutics 的 52 周低点为 28.66 美元，52 周高点为 91.00 美元。该股票的市值为 55.1 亿美元，市盈率为 146.76，贝塔值为 0.36。</p>
</div><p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The firm had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The company's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the firm earned $0.17 EPS. As a group, equities analysts anticipate that Corcept Therapeutics will post 0.35 earnings per share for the current year.</p>
<div class="lb-trans"><p>Corcept Therapeutics（纳斯达克：CORT - 获取免费报告）在 4 月 30 日最后发布了季度财报。这家生物技术公司报告季度每股收益（EPS）为（0.30）美元，低于共识预期的（0.11）美元，差距为（0.19）美元。该公司季度收入为 1.649 亿美元，而共识预期为 1.8583 亿美元。Corcept Therapeutics 的股本回报率为 7.40%，净利润率为 6.14%。该公司季度收入同比增长 4.9%。去年同期，该公司每股收益为 0.17 美元。整体来看，股票分析师预计 Corcept Therapeutics 在当前年度将发布 0.35 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Corcept Therapeutics news, Director G Leonard Baker, Jr. purchased 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was bought at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the purchase, the director directly owned 1,146,631 shares of the company's stock, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the completion of the sale, the chief executive officer owned 2,918,326 shares in the company, valued at approximately $146,120,582.82. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 66,198 shares of company stock valued at $2,851,169. Company insiders own 20.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Corcept Therapeutics 的新闻中，董事 G Leonard Baker, Jr.在 3 月 17 日的交易中购买了 100,000 股该公司的股票。该股票的平均购买价格为每股 33.14 美元，总价值为 3,314,000.00 美元。完成购买后，该董事直接持有 1,146,631 股该公司的股票，价值约为 37,999,351.34 美元。此次交易使其持股增加了 9.55%。该购买在 SEC 的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Joseph K. Belanoff 在 3 月 25 日的交易中出售了 26,198 股 Corcept Therapeutics 的股票。该股票的平均售价为 50.07 美元，总交易额为 1,311,733.86 美元。出售完成后，首席执行官在公司中持有 2,918,326 股，价值约为 146,120,582.82 美元。此次交易使其持股减少了 0.89%。该出售的披露信息可在 SEC 备案中找到。在过去三个月中，内部人士共出售了 66,198 股公司股票，价值为 2,851,169 美元。公司内部人士持有 20.70% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On Corcept Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Corcept Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Torren Management LLC purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $25,000. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics in the third quarter worth about $25,000. Clearstead Advisors LLC boosted its position in Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $31,000. Finally, Hantz Financial Services Inc. grew its holdings in shares of Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 524 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该股票的持有。Torren Management LLC 在第四季度购买了 Corcept Therapeutics 的新头寸，价值约为 25,000 美元。Advisory Services Network LLC 在第三季度购买了 Corcept Therapeutics 的新股份，价值约为 25,000 美元。Clearstead Advisors LLC 在第三季度将其在 Corcept Therapeutics 的持仓增加了 163.6%。Clearstead Advisors LLC 现在持有 311 股该生物技术公司的股票，价值为 26,000 美元，此前在上个季度又购买了 193 股。Atlas Capital Advisors Inc.在第四季度购买了 Corcept Therapeutics 的新股份，价值约为 31,000 美元。最后，Hantz Financial Services Inc.在第四季度将其在 Corcept Therapeutics 的持仓增加了 113.7%。Hantz Financial Services Inc.现在持有 985 股该生物技术公司的股票，价值 34,000 美元，此前在此期间又购买了 524 股。93.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Corcept Therapeutics</h2>
<div class="lb-trans"><h2>关于 Corcept Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.</p>
<div class="lb-trans"><p>Corcept Therapeutics 是一家临床阶段的生物制药公司，专注于发现和开发调节皮质醇作用的药物，皮质醇是一种与多种严重代谢、肿瘤和精神疾病相关的激素。该公司的科学平台专注于选择性靶向糖皮质激素受体，以抵消过量皮质醇的有害后果，这一策略旨在解决具有显著未满足医疗需求的疾病。</p>
</div><p>The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.</p>
<div class="lb-trans"><p>该公司的旗舰上市产品 Korlym（米非司酮）已在美国获得批准，用于治疗因库欣综合症引起的高血糖，适用于患有 2 型糖尿病或葡萄糖耐受不良且不适合手术的患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Corcept Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Corcept Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CORT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Corcept Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Corcept Therapeutics 吗？</h2>
</div><p>Before you consider Corcept Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Corcept Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Corcept Therapeutics 并不在名单上。</p>
</div><p>While Corcept Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corcept Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating

Market Beat

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

美国制药 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

标普全球医疗股指数 ETF - iShares

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

Corcept Therapeutics（纳斯达克股票代码：CORT）被 Zacks Research 上调至持有评级